Untitled - Roche Trasplantes

More documents

Recommendations

Info

EARLY DIAGNOSIS OF CHRONIC ALLOGRAFT NEPHROPATHY BY MEANS OF PROTOCOL BIOPSIES 17. Fernando GC, Griffin MD, Grande JP, Lager DJ, Gloor JM, Velosa JA, Larson TS, Stegall MD. Development of chronic allograft nephropathy (CAN) in low risk kidney transplant recipients. Am J Transplant 2004; 4 (S8): 278. 18. Kupypers DR, Chapman JR, O’Connell PJ, Allen RDM, Nankivell BJ. Predictors of renal transplant histology at three months. Transplantation 1999; 67: 1222-30. 19. Solez K, Vincenti F, Filo R. Histopathological findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 kidney transplant study group. Transplantation 1998; 66: 1736-40. 20. Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, Claesson K, Castagneto M, Campistol JM, Hutchison B, Burke JT, Yilmaz S, Hayry P, Neylan JF. Sirolimusbased therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004 Jun; 4: 953-61. 21. Merville P, Berge F, Deminiere C, Morel D, Chong G, Durand D, Rostaing L, Mourad G, Potaux L. Lower incidence of chorinc allograft nephropathy at 1 year post-transplantation in patients treated with Mycophenolate mofetil. Am J Transplant 2004; 4: 1769-75. 22. Schwarz A, Mengel M, Gwinner W, Radermacher J, Hiss, Kreipe H, Haller H. Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study. Kidney Int 2005; 67: 341-8. 23. Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT, Rollin H, Hammond JA, Whisenant T, Lanigan CM, Head SR, Salomon DR. De novo kidney transplantation without the use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776-85. 24. Nankivell BJ, Borrows RJ, Fung CL-S, O’Connell PJ, Chapman JR, Allen RDMA. Delta analysis of post transplantation tubulointerstitial damage. Transplantation 2004; 78: 434-41. 25. Nankivell BJ, Borrows RJ, Fung CL-S, O’Connell PJ, Allen RDMA, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242-9. 26. Rush D, Nickerson P, Gough J, McKenna R, Grimm P, Cheang M, Trpkov K, Solez K, Jeffery J. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9: 2129-34. 27. Rush D. No benefit of protocol biopsies in renal transplant patients receiving Tacrolimus and Mycophenolate Mofetil: a multicentre randomized study. Transplantation 2006: 82 (1) abstract 843. 28. Choi BS, Shin MJ, Shin SJ, Kim YS, Choi YJ, Kim YS, et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center. Am J Transplant 2005; 5 (6): 1354-60. 29. Moreso F, Ibernon M, Goma M, Carrera M, Fulladosa X, Hueso M, Gil-Vernet S, Cruzado JM, Torras J, Grinyó JM, Serón D. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006 Apr; 6 (4): 747-52. 27
BIOPSIA DE PROTOCOLO EN EL TRASPLANTE RENAL 30. Birk PE, Stannard KM, Konrad HB, Blydt-Hansen TD, Ogborn MR, Cheang MS, et al. Surveillance biopsies are superior to functional studies for the diagnosis of acute and chronic renal allograft pathology in children. Pediatr Transplant 2004; 8 (1): 29-38. 31. Miyagi M, Ishikawa Y, Mizuiri S, Aikawa A, Ohara T, Hasegawa A. Significance of subclinical rejection in early renal allograft biopsies for chronic allograft dysfunction. Clin Transplant 2005; 19 (4): 456-65. 32. Nickerson P, Jeffery J, Gough J, Grimm P, McKenna R, Birk P, et al. Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: a pilot study. Journal of the American Society of Nephrology 1999; 10 (8): 1801-5. 33. Gloor JM, Cohen AJ, Lager DJ, Grande JP, Fidler ME, Velosa JA, et al. Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation 2002; 73 (12): 1965-8. 34. Kanetsuna Y, Yamaguchi Y, Toma H, Tanabe K. Histological evaluation of renal allograft protocol biopsies in the early period and 1 year after transplantation. Clin Transplant 2003; 17 Suppl. 10: 25-9. 35. Shishido S, Asanuma H, Nakai H, Mori Y, Satoh H, Kamimaki I, et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003; 14 (4): 1046-52. 36. Serón D, Moreso F, Bover J, Condom E, Gil-Vernet S, Canas C, et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 51 (1): 310-6. 37. Colvin RB. Chronic allograft nephropathy. N Engl J Med 2003; 349: 2288-90. 38. Nankivell BJ, Borrows RJ, Fung CL-S, O’Connell PJ, Chapman JR, Allen RDMA. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-65. 39. Myslak M, Amer H, Morales P, Fidler ME, Gloor JM, Larson TS, Stegall MD, Cosio FG. Interpreting post-transplant proteinuria in patients with proteinuria pre-transplant. Am J Transplant 2006; 6: 1660-85. 40. Regele H, Bohmig GA, Habicht A, Gollowitzer D, Schillinger M, Rockenschaub S, Watschinger B, Kerjaschki D, Exner M. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002 Sep; 13 (9): 2371-80. 41. Hamburger J, Crosnier J, Dormont J. Observations in patients with a well tolerated homotransplant kidney: possibility of a new secondary disease. Ann N Y Acad Sci 1964; 120: 558-77. 42. Racusen L, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickleit V, Randhawa P, Regele H, Serón D, Seshan S, Sund S, Trpkov K. Antibody-mediated rejection criteria – an addition to the Banff ’97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-14. 28
Page 5 and 6: DRUG Edificio Vértice Antonio Lóp
Page 7 and 8: BIOPSIA DE PROTOCOLO EN EL TRASPLAN
Page 29: BIOPSIA DE PROTOCOLO EN EL TRASPLAN
Page 34 and 35: DIAGNÓSTICO PRECOZ DEL RECHAZO SUB
Page 52: DIAGNÓSTICO PRECOZ DEL RECHAZO SUB
Page 74 and 75: ADAPTACIÓN GLOMERULAR EVALUADA MED
Page 80 and 81:
ADAPTACIÓN GLOMERULAR EVALUADA MED
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92:
Page 95 and 96:
BIOPSIA DE PROTOCOLO EN EL TRASPLAN
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
show all

Untitled - Roche Trasplantes

Create successful ePaper yourself

Delete template?

Save as template?